Intra-day Buy Alert - Adolor Corporation (ADLR)

FOR IMMEDIATE RELEASE
West Bloomfield, Michigan, United States of America (Free-Press-Release.com) July 12, 2011 -- Adolor Corporation is currently pulling back and bouncing off it's 61.8% Fibonacci Retracement level on low volume. This presents a nice buying opportunity for those wanting to own the stock or wanting to add to their position.

Adolor has been on a run since it's breakout on June 16, 2011. ADLR has moved up almost 100% from it's breakout base at $1.50. According to Chief Financial Analyst, Joseph P. Capaldi II at Professional Trading (ProTSC.com), healthy moves in equities come with low volume pull backs. ADLR traded intra-day at only 336K shares compared with one million on it's breakout day. These days are impossible to predict, but are nice opportunities to add or establish positions in stocks on the move.

Adolor Corporation (ADLR) is a bio-pharmaceutical company focused on the development and commercialization of novel prescription pain and pain-management products. Adolor's mission addresses a simple goal: to provide enhanced relief for the millions of people who suffer from pain each year.

Michael J. Fox Foundation for Parkinson's Research awarded Adolor two rounds of funding to support their development of CAMORs for the treatment of LID associated with Parkinson's disease.

Adolor Corporation (ADLR) , currently trading at $2.50 per share, is undervalued according to Capaldi at Professional Trading Systems Corporation (ProTSC.com). According to Capaldi, Adolor has five (5) unique drugs in it's pipeline. ENTEREG®, which is already approved for limited market for in-hospital use and is seeking wider approval, ADL5945, ADL7445, ADL6906 and Camors for Parkinson's disease.

When compared to Pharmasset, Inc. (VRUS) , currently trading at $126.00 per share with no drugs currently approved for market, Adolor Corporation (ADLR) is the next big drug company to significantly gap up. Valuations managers say Adolor is being quietly acquired by funds managers and other drug companies. Glaxo Smith Kline (GSK) , a leading health care company, has partnered with Adolor to bring ENTEREG® to market and has purchased a stake in the company.

Adolor Corporation (ADLR) , currently trading at $2.50 per share, Joe Capaldi projects $125.00 per share when one (1) of their next four (4) drugs reaches market.

Links:
http://www.adolor.com/research/index1.asp?page=r-d-pipeline

ADLR Buy Alert     Adolor     bio tech stocks     bio tech stocks breakout     Joe Capaldi     Joseph Capaldi     ProTSC     Stock Recommendations